Recent Updates
Recently added Catalysts
ALT Positive Sentiment Score: 60/100

Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

Thursday, February 20, 2025 1 min read
Key Takeaway: Altimmune, Inc. will report its fourth quarter and full year 2024 financial results on February 27, 2025. The company's management will discuss these results and provide a business update during a conference call scheduled for 8:30 am ET on the same day. The call will be accessible via webcast on Altimmune's Investor Relations website. Altimmune is focusing on developing next-generation peptide-based therapeutics, including pemvidutide for obesity treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • Altimmune is set to report its financial results, indicating transparency and accountability.
  • The company continues to develop innovative therapeutics, showcasing its commitment to innovation.
  • The live webcast offers accessibility for stakeholders to engage with the company.

Full Press Release Details

GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025.
Altimmune management will host a conference call at 8:30 am E.T. on February 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.
Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Chief Financial Officer
Inizio Evoke, Biotech
Danielle.cantey@inizioevoke.com
This press release was published by a CLEAR® Verified individual.

Frequently Asked Questions

When will Altimmune announce its 2024 financial results?

Altimmune will report its financial results on February 27, 2025.

What time is Altimmune's conference call scheduled?

The conference call will take place at 8:30 am E.T. on February 27.

How can I access the conference call?

Participants can register to receive dial-in details for the call.

What is Altimmune's focus in biopharmaceuticals?

Altimmune specializes in next-generation peptide-based therapeutics.

What therapeutic is Altimmune developing for obesity?

Altimmune is developing pemvidutide, a dual receptor agonist.

Tags: ALT Viatris Investor Conferences Healthcare Altimmune pemvidutide financial results obesity treatment clinical-stage biopharmaceutical
Last updated: Feb 20, 2025